226 related articles for article (PubMed ID: 30946887)
1. Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA Study.
Wykoff CC; Shah C; Dhoot D; Coleman HR; Thompson D; Du W; Baker K; Vitti R; Berliner AJ; Metzig C; Saroj N
Ophthalmology; 2019 Aug; 126(8):1171-1180. PubMed ID: 30946887
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
Heier JS; Korobelnik JF; Brown DM; Schmidt-Erfurth U; Do DV; Midena E; Boyer DS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Vitti R; Berliner AJ; Zeitz O; Metzig C; Holz FG
Ophthalmology; 2016 Nov; 123(11):2376-2385. PubMed ID: 27651226
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal aflibercept for diabetic macular edema.
Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM
Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
[TBL] [Abstract][Full Text] [Related]
6. Effect of Baseline Subretinal Fluid on Treatment Outcomes in VIVID-DME and VISTA-DME Studies.
Korobelnik JF; Lu C; Katz TA; Dhoot DS; Loewenstein A; Arnold J; Staurenghi G
Ophthalmol Retina; 2019 Aug; 3(8):663-669. PubMed ID: 31103642
[TBL] [Abstract][Full Text] [Related]
7. Higher-Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal Fluid Index.
Ehlers JP; Uchida A; Hu M; Figueiredo N; Kaiser PK; Heier JS; Brown DM; Boyer DS; Do DV; Gibson A; Saroj N; Srivastava SK
Ophthalmol Retina; 2019 Dec; 3(12):1056-1066. PubMed ID: 31473172
[TBL] [Abstract][Full Text] [Related]
8. Baseline Factors Affecting Changes in Diabetic Retinopathy Severity Scale Score After Intravitreal Aflibercept or Laser for Diabetic Macular Edema: Post Hoc Analyses from VISTA and VIVID.
Dhoot DS; Baker K; Saroj N; Vitti R; Berliner AJ; Metzig C; Thompson D; Singh RP
Ophthalmology; 2018 Jan; 125(1):51-56. PubMed ID: 28764888
[TBL] [Abstract][Full Text] [Related]
9. [New perspectives in the approach to diabetic macular edema. Aflibercept therapy].
Ruiz-Moreno JM
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():24-8. PubMed ID: 25925048
[TBL] [Abstract][Full Text] [Related]
10. Outcomes in Patients with Diabetic Macular Edema Requiring Cataract Surgery in VISTA and VIVID Studies.
Moshfeghi AA; Thompson D; Berliner AJ; Saroj N
Ophthalmol Retina; 2020 May; 4(5):481-485. PubMed ID: 31924543
[TBL] [Abstract][Full Text] [Related]
11. Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept.
Gonzalez VH; Boyer DS; Schmidt-Erfurth U; Heier JS; Gordon C; Benz MS; Marcus DM; Sabates NR; Vitti R; Kazmi H; Berliner AJ; Soo Y; Zhu X; Moini H; Zeitz O; Sandbrink R; Do DV
Retina; 2015 Apr; 35(4):687-94. PubMed ID: 25621943
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.
Clark WL; Boyer DS; Heier JS; Brown DM; Haller JA; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Campochiaro PA
Ophthalmology; 2016 Feb; 123(2):330-336. PubMed ID: 26522708
[TBL] [Abstract][Full Text] [Related]
13. Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies.
Staurenghi G; Feltgen N; Arnold JJ; Katz TA; Metzig C; Lu C; Holz FG;
Br J Ophthalmol; 2018 Jul; 102(7):954-958. PubMed ID: 29051325
[TBL] [Abstract][Full Text] [Related]
14. Retinal Fluid Volatility Associated With Interval Tolerance and Visual Outcomes in Diabetic Macular Edema in the VISTA Phase III Trial.
Ehlers JP; Uchida A; Sevgi DD; Hu M; Reed K; Berliner A; Vitti R; Chu K; Srivastava SK
Am J Ophthalmol; 2021 Apr; 224():217-227. PubMed ID: 33253664
[TBL] [Abstract][Full Text] [Related]
15. Impact of Baseline Retinal Nonperfusion and Macular Retinal Capillary Nonperfusion on Outcomes in the COPERNICUS and GALILEO Studies.
Feltgen N; Ogura Y; Boscia F; Holz FG; Korobelnik JF; Brown DM; Heier JS; Stemper B; Rittenhouse KD; Asmus F; Ahlers C; Vitti R; Saroj N; Mitchell P
Ophthalmol Retina; 2019 Jul; 3(7):553-560. PubMed ID: 31277796
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.
Campochiaro PA; Clark WL; Boyer DS; Heier JS; Brown DM; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Haller JA
Ophthalmology; 2015 Mar; 122(3):538-44. PubMed ID: 25315663
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.
Brown DM; Heier JS; Clark WL; Boyer DS; Vitti R; Berliner AJ; Zeitz O; Sandbrink R; Zhu X; Haller JA
Am J Ophthalmol; 2013 Mar; 155(3):429-437.e7. PubMed ID: 23218699
[TBL] [Abstract][Full Text] [Related]
18. Functional outcomes of sustained improvement on Diabetic Retinopathy Severity Scale with intravitreal aflibercept in the VISTA and VIVID trials.
Dhoot DS; Moini H; Reed K; Du W; Vitti R; Berliner AJ; Singh RP
Eye (Lond); 2023 Jul; 37(10):2020-2025. PubMed ID: 35440699
[TBL] [Abstract][Full Text] [Related]
19. Can subthreshold micropulse yellow laser treatment change the anti-vascular endothelial growth factor algorithm in diabetic macular edema? A randomized clinical trial.
Kanar HS; Arsan A; Altun A; Akı SF; Hacısalihoglu A
Indian J Ophthalmol; 2020 Jan; 68(1):145-151. PubMed ID: 31856493
[TBL] [Abstract][Full Text] [Related]
20. Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid.
Jaffe GJ; Kaiser PK; Thompson D; Gibson A; Saroj N; Vitti R; Berliner AJ; Heier JS
Ophthalmology; 2016 Sep; 123(9):1856-64. PubMed ID: 27369111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
